upndown1313

Is Merck's New Obesity Drug Candidate in Serious Trouble?

Discontinuations due to GI- and psychiatric-related AEs were 0.7%, 1.7%, 2.7% and 4.6%, 8.9%, 12.5%, respectively, for Pbo, 2- and 4- mg groups. Most AEs were mild to moderate in intensity.
Conclusions: Treatment with taranabant for 52 wks led to clinically meaningful weight loss and improvements in metabolic parameters with a favorable risk/benefit profile.